PEP503

DRUG2 trials

Sponsors

PharmaEngine

Conditions

Head and Neck Squamous Cell CarcinomaRectal Cancer

Phase 1

A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer

TerminatedNCT02465593

PharmaEngineRectal Cancer

Start: 2015-06-30End: 2021-07-28Updated: 2022-01-11

A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer

TerminatedNCT02901483

PharmaEngineHead and Neck Squamous Cell Carcinoma

Start: 2016-10-11End: 2020-08-17Updated: 2022-01-11

Related Papers

Results of phase Ib/II trial of PEP503 (NBTXR3, radioenhancer) with chemoradiotherapy in patients with rectal cancer

Nanomedicine2025-04-211 citations

A Phase Ib/II Trial of PEP503 (NBTXR3, Radioenhancer) with Radiotherapy and Chemotherapy in Patients with Rectal Cancer

Nanomedicine2023-03-0110 citations

PEP503 (NBTXR3), a radioenhancer, in combination with concurrent chemoradiation (CCRT) in locally advanced or recurrent head and neck squamous cell carcinoma (HNSCC): Dose-finding of a phase 1b/2 trial.

Journal of Clinical Oncology2022-06-012 citations

Phase 1b/ 2 study of a radio-enhancer, PEP503 (NBTXR3), in combination with concurrent chemo-radiation in locally advanced or unresectable rectal cancer.

Journal of Clinical Oncology2022-06-012 citations

A new radio-enhancer, PEP503 (NBTXR3), in combination with concurrent chemoradiation in locally advanced or unresectable rectal cancer: The dose-finding part of a phase I/II trial.

Journal of Clinical Oncology2021-01-2028 citations

Hepatocellular carcinoma and liver metastasis treated by hafnium oxide nanoparticles activated by SBRT: A phase I/II trial.

Journal of Clinical Oncology2019-01-292 citations

A phase I/II trial of hafnium oxide nanoparticles activated by radiotherapy in hepatocellular carcinoma and liver metastasis

Annals of Oncology2018-06-013 citations